TIDMNSCI
NetScientific PLC
19 November 2020
NetScientific plc
("NetScientific" or the "Company")
ProAxsis Limited appoints DiaPharma as distributor to key North
America region
London, UK - 19 November 2020 - NetScientific plc (AIM: NSCI),
the life sciences, technology investment and commercialisation
company, announces that its portfolio company ProAxsis Limited
("ProAxsis"), today announced that it has appointed DiaPharma Group
Inc. ("DiaPharma") as the exclusive distributor of its portfolio of
respiratory research assays for the key North America region.
Based in Ohio, DiaPharma has specialised in the
commercialisation of products within the research and diagnostic
fields in the United States and Canada since it was founded in
1997. This partnership agreement provides them with exclusive
access to ProAxsis' activity-based immunoassay kits for the
quantification of the active forms of neutrophil elastase,
proteinase 3 and cathepsin G.
Speaking about the agreement, Dr David Ribeiro, CEO of ProAxsis,
said: "We're delighted to have reached this agreement with
DiaPharma. Finding a suitable commercial partner for our portfolio
in North America was a key short-term objective for the company and
we are very excited about partnering with a company that has such
experience in the commercialisation of research-focused products in
this region of substantial commercialisation potential."
With over 20 years of expertise in proteolytic enzyme activity
assays, DiaPharma sees a natural fit with ProAxsis. Olivia
Stricker, PhD, Business Development Manager at DiaPharma, added:
"We're pleased to have gained access to the innovative
ProteaseTag(R) technology of ProAxsis and look forward to providing
our customers with solutions for protease-focused research at the
bench and clinical trials."
John Clarkson, Chairman of NetScientific Plc said: "Following
the acquisition of all the outside shareholdings, this is another
significant step in the continued planned business growth of
ProAxsis and accelerating progress into international markets.
ProAxsis has made strong progress this year and this latest
announcement illustrates the increased potential for its
respiratory diagnostics offering in a post COVID-19 world. This
also reinforces NetScientific's strategy of expanding
cross-Atlantic bridges for our portfolio companies."
NetScientific holds 95% of ProAxsis on a fully diluted
basis.
# # #
ProAxsis Limited appoints distributor to key North America
region
ProAxsis Limited (www.proaxsis.com), the Belfast-based
diagnostics company specialising in the measurement of active
proteases and other inflammatory biomarkers, today announces that
it has appointed DiaPharma Group Inc. as the exclusive distributor
of its portfolio of respiratory research assays for the North
America region.
Based in Ohio, DiaPharma has specialised in the
commercialisation of products within the research and diagnostic
fields in the United States and Canada since it was founded in
1997. This partnership agreement provides them with exclusive
access to ProAxsis' activity-based immunoassay kits for the
quantification of the active forms of neutrophil elastase,
proteinase 3 and cathepsin G.
Speaking about the agreement, Dr David Ribeiro, CEO of ProAxsis,
said: "We're delighted to have reached this agreement with
DiaPharma. Finding a suitable commercial partner for our portfolio
in North America was a key short-term objective for the company and
we are very excited about partnering with a company that has such
experience in the commercialisation of research-focused products in
this region of substantial commercialisation potential."
With over 20 years of expertise in proteolytic enzyme activity
assays, DiaPharma sees a natural fit with ProAxsis. Olivia
Stricker, PhD, Business Development Manager at DiaPharma, added:
"We're pleased to have gained access to the innovative
ProteaseTag(R) technology of ProAxsis and look forward to providing
our customers with solutions for protease-focused research at the
bench and clinical trials."
Any enquiries concerning ProAxsis' work with proteases and other
inflammatory biomarkers can be directed to info@proaxsis.com.
To learn more about DiaPharma, please visit
www.diapharma.com.
About ProAxsis
ProAxsis Limited is a commercial-stage diagnostics company,
based in Northern Ireland, and with a rapidly growing global client
list of pharmaceutical companies and academic laboratories. The
company has developed activity-based immunoassays for the specific
quantification of the active form of Neutrophil Elastase,
Proteinase 3 and Cathepsin G.
In addition to proteases, the company also has significant
expertise in the measurement of other inflammatory biomarkers,
including IL-6, IL-8 and TNF-alpha.
Aside from the provision of assays, ProAxsis is able to offer a
sample analysis service at its purpose-built laboratory facility in
Belfast and is currently supporting a number of pharmaceutical
company-sponsored Phase I, II and III clinical trials.
ProAxsis became a fully owned subsidiary of Netscientific plc in
October 2020.
To learn more about ProAxsis, please visit www.proaxsis.com
.
About DiaPharma
DiaPharma Group, Inc. in West Chester, Ohio is a privately held
distributor of superior biotechnology products throughout the US
and Canada. For over 25 years, DiaPharma has been the exclusive
distributor of Chromogenix, a gold standard in chromogenic
substrate technology, and have grown to represent assays for
hemostasis and thrombosis, as well as unique biomarkers for organ
damage, oncology, autoimmunity, infectious diseases, metabolic
syndrome, and ecotoxicology. The product menu ranges from
chromogenic substrates, activity assays, ELISA kits and antibodies
to instrumentation. DiaPharma's team provides strong technical
competence and experience to clinical and research scientists to
ensure customer expectations will be met or exceeded.
To learn more about DiaPharma, please visit
www.diapharma.com.
# # #
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014. Following the
publication of this announcement, this inside information is now
considered to be in the public domain.
For more information, please contact:
NetScientific
Ilian Iliev, CEO Tel: +44 (0)20 3514 1800
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel Tel: +44 (0)20 7220 1666
About NetScientific
NetScientific is a life sciences, technology investment and
commercialisation Group, leveraging trans-Atlantic relationships
and global opportunities to deliver shareholder value.
For more information, please visit the website at www.NetScientific.net
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAXFPFAPEFFA
(END) Dow Jones Newswires
November 19, 2020 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024